{
    "clinical_study": {
        "@rank": "56971", 
        "acronym": "STA", 
        "arm_group": [
            {
                "arm_group_label": "Prednisone 1 week", 
                "arm_group_type": "Experimental", 
                "description": "Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks."
            }, 
            {
                "arm_group_label": "Prednisone 6 weeks", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral 30 mg/day of prednisone will be administered as the initial dose for the treatment of SAT in first week,then tapered by 5mg every 1 week,the duration of prednisone will be 6 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute\n      Thyroiditis\n\n      The investigators hypothesize that less adverse reactions will be observed, comparing with\n      the guidelines recommend. The recurrence rate, adrenal insufficiency, temporary and\n      permanent hypothyroidism aren't significant difference."
        }, 
        "brief_title": "Short-term Prednisone to Treat STA Study(SPTSS)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Subacute Thyroiditis", 
        "condition_browse": {
            "mesh_term": [
                "Thyroiditis", 
                "Thyroiditis, Subacute"
            ]
        }, 
        "detailed_description": {
            "textblock": "Comparing with the guidelines recommend, short-term (one week)prednisone and nsaids\n      following up next week to treat moderate and severe subacute thyroiditis will be assessed.\n\n      The patients in wards will be assessed from temperature,erythrocyte sedimentation\n      rate,C-reactive protein,local pain and goiter.The random treatment will be executed in\n      moderate and severe SAT after informed consent be signed.\n\n      Subjects will be monitored once every 2 weeks.If patients complained of pain in their neck\n      or if the erythrocyte sedimentation rate is still high,after discontinuation of prednisone,\n      prednisone treatment will be resumed in moderate and severe subject and non-steroidal\n      anti-inflammatory drugs will be used in mild subject.Anti-ulcer drugs will be administered\n      to all patients.\n\n      The endpoint of the study are efficiency and safety of short-term prednisone treating. The\n      investigators will assess adrenal insufficiency (such as anorexia, nausea, vomiting,\n      abdominal pain),steroid withdrawal syndrome, recurrence rate and hypothyroidism. The\n      investigators will observe erythrocyte sedimentation rate,pain,steroid level and thyroid\n      function."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18-70 years patients with Moderate and severe subacute thyroiditis\n\n        Exclusion Criteria:\n\n          -  adrenal cortical dysfunction,\n\n          -  use of corticosteroids in nearly three months,\n\n          -  mild subacute thyroiditis,\n\n          -  non-onset STA,\n\n          -  family history of diabetes,\n\n          -  gastric ulcer,\n\n          -  the special medication history,\n\n          -  heart\uff0cliver and renal insufficiency,\n\n          -  tumors,\n\n          -  tuberculosis and\n\n          -  poor compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01837433", 
            "org_study_id": "XinqiaoH-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prednisone 1 week", 
                "description": "Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.", 
                "intervention_name": "Prednisone 1 week", 
                "intervention_type": "Drug", 
                "other_name": "Glucocorticoid"
            }, 
            {
                "arm_group_label": "Prednisone 6 weeks", 
                "description": "Guidelines recommend", 
                "intervention_name": "Prednisone 6 weeks", 
                "intervention_type": "Drug", 
                "other_name": "Glucocorticoid"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucocorticoids", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Efficacy", 
            "safety", 
            "short", 
            "term", 
            "subacute thyroiditis"
        ], 
        "lastchanged_date": "May 26, 2014", 
        "location": {
            "contact": {
                "email": "jasonduan2011@gmail.com", 
                "last_name": "Lian Duan, Master", 
                "phone": "+86 13637936332"
            }, 
            "facility": {
                "address": {
                    "city": "Chongqing", 
                    "country": "China", 
                    "state": "Chongqing", 
                    "zip": "400037"
                }, 
                "name": "The Second Affiliated Hospital, Third Military Medical University"
            }, 
            "investigator": {
                "last_name": "Hongting Zheng, Ph D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis", 
        "other_outcome": {
            "description": "Such as,cushing appearance; female hirsutism, menstrual disorders, impotence in men; gastrointestinal ulcers; psychiatric symptoms: anxiety, agitation, fatigue", 
            "measure": "Other side effects of prednisone", 
            "safety_issue": "Yes", 
            "time_frame": "42 days"
        }, 
        "overall_contact": {
            "email": "jasonduan2011@gmail.com", 
            "last_name": "Lian Duan, Master", 
            "phone": "+86 13637936332"
        }, 
        "overall_official": {
            "affiliation": "Department of Endocrinology, The Second Affiliated Hospital, Third Military Medical University, Chongqing, People's Republic of China.", 
            "last_name": "Hongting Zheng, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will observe change of erythrocyte sedimentation rate from >20mm/h to normal,C-reactive protein,pain and goiter disappear after 14 days.", 
            "measure": "The Efficiency of experimental group comparing with control group during 14 days", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01837433"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Xinqiao Hospital of Chongqing", 
            "investigator_full_name": "Lian Duan", 
            "investigator_title": "Clinical Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The recurrence will be defined:local tenderness, goiter, inflammatory factors such as erythrocyte sedimentation rate, C-reactive protein increased during 180 days.", 
                "measure": "recurrence rate", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }, 
            {
                "description": "change in thyroid function:from hyperthyroidism on baseline to hypothyroidism after 180 days.", 
                "measure": "hypothyroidism", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }, 
            {
                "description": "The Symptom such as anorexia, nausea, vomiting, abdominal pain, fatigue, weakness, collapse, muscle pain, joint pain, weight loss, orthostatic hypotension, lethargy and depression.", 
                "measure": "Adrenal insufficiency after withdraw in experimental group and control group.", 
                "safety_issue": "Yes", 
                "time_frame": "42 days"
            }, 
            {
                "description": "Glucose change when taking medicine:from normal blood glucose on baseline to hyperglycemia at the special time during medication.", 
                "measure": "Change of blood glucose in experimental group and control group.", 
                "safety_issue": "Yes", 
                "time_frame": "42 days"
            }, 
            {
                "description": "We will measure blood pressure before and after withdraw prednisone in experimental and control group.", 
                "measure": "Change of blood pressure in experimental and control group during medication.", 
                "safety_issue": "Yes", 
                "time_frame": "42 days"
            }, 
            {
                "description": "We will measure Bone metabolism markers before and after withdraw prednisone in experimental and control group.", 
                "measure": "Bone metabolism after withdraw in experimental group and control group.", 
                "safety_issue": "Yes", 
                "time_frame": "42 days"
            }, 
            {
                "description": "We will measure Lipids before and after withdraw prednisone in experimental and control group.", 
                "measure": "Change of Lipids in experimental and control group during medication.", 
                "safety_issue": "Yes", 
                "time_frame": "42 days"
            }
        ], 
        "source": "Xinqiao Hospital of Chongqing", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xinqiao Hospital of Chongqing", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}